SUPPLEMENTAL MATERIAL

Three-year Outcomes with the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-analysis from the ABSORB Randomized Trials

Ziad A. Ali, MD, DPhil; Runlin Gao, MD; Takeshi Kimura, MD; Yoshinobu Onuma, MD, PhD; Dean J. Kereiakes, MD; Stephen G. Ellis, MD; Bernard Chevalier, MD; Minh-thien Vu, MS; Zhen Zhang, PhD; Charles A. Simonton, MD; Patrick W. Serruys, MD, PhD; Gregg W. Stone, MD

Table 1. Major characteristics of the four randomized ABSORB trials

	ABSORB II[1]	ABSORB Japan[2]	ABSORB China[3]	ABSORB III[4]
ClinicalTrials.gov identifier	NCT01425281	NCT01844284	NCT01923740	NCT01751906
Number of centers	46	38	24	193
Number of randomized patients	501	400	480	2,008
- assigned to BVS	335	266	241	1,322
- assigned to CoCr-EES	166	134	239	686
Number of study lesions allowed	2	2	2	2
Number of study vessels allowed*	2	2	2	2
Target lesion reference vessel diameter	Maximum lumen diameter 2.25 to 3.8 mm by online QCA	≥2.5 to ≤3.75 mm by online QCA or visual assessment	≥2.5 to ≤3.75 mm by online QCA or visual assessment	≥2.5 to ≤3.75 mm by visual assessment (QCA or imaging allowed)
Target lesion length	≤48 mm	≤24 mm	≤24 mm	≤24 mm
Device overlap allowed	Yes	For bailout only	For bailout only	For bailout only
3-year clinical follow-up complete	316 (96.7%)	256 (96.2%)	236 (97.9%)	1,280 (96.8%)
Routine angiographic follow-up	At 3 years	At 13 months	At 1 year	No
Primary endpoint	Angiographic vasomotion at 3 years	TLF at 1 year	Angiographic in-segment late loss at 1 year	TLF at 1 year
Total duration of follow-up	5 years	5 years	5 years	5 years

*Maximum 1 lesion per vessel. QCA = quantitative coronary angiography; TLF = target lesion failure

Table 2. Baseline clinical features and antiplatelet medications

	BVS (N=2164)	CoCr-EES (N=1225)	P value
Age (years)	62.9 ± 10.8	62.5 ± 10.4	0.83
Male	1568/2161 (72.6%)	884/1223 (72.3%)	0.90
Body mass index (kg/m^2)	28.8 ± 5.9	28.5 ± 5.7	0.92
Diabetes mellitus	652/2159 (30.2%)	367/1223 (30.0%)	0.86
- Insulin-treated	207/2159 (9.6%)	120/1223 (9.8%)	0.77
Hypertension (medically treated)	1622/2161 (75.1%)	902/1223 (73.8%)	0.91
Hyperlipidemia (medically treated)	1540/2161 (71.3%)	847/1223 (69.3%)	0.45
Current smoking	491/2161 (22.7%)	291/1223 (23.8%)	0.97
Prior PCI	716/2161 (33.1%)	372/1221 (30.5%)	0.78
Prior CABG	69/2161 (3.2%)	31/1221 (2.5%)	0.53
Prior myocardial infarction	457/2143 (21.3%)	268/1218 (22.0%)	0.36
Renal insufficiency*	145/1557 (9.3%)	76/922 (8.2%)	0.98
Pre-PCI evidence of ischemia			
- Silent ischemia	253/2160 (11.7%)	126/1223 (10.3%)	0.58
- Stable angina	1194/2160 (55.3%)	652/1223 (53.3%)	0.36
- Unstable angina	603/2160 (27.9%)	379/1223 (31.0%)	0.75
- Recent MI	66/2160 (3.1%)	49/1223 (4.0%)	0.60
- Post-MI angina	16/2160 (0.7%)	8/1223 (0.7%)	0.39
- None	28/2160 (1.3%)	9/1223 (0.7%)	0.15
Aspirin**	2108/2161 (97.5%)	1183/1223 (96.7%)	0.71
Platelet P2Y12 receptor inhibitor use**	2129/2161 (98.5%)	1198/1223 (98.0%)	0.18
- Clopidogrel or ticlopidine	1615/2129 (75.9%)	945/1198 (78.9%)	0.43
- Prasugrel or ticagrelor	514/2129 (24.1%)	253/1198 (21.1%)	0.43
Glycoprotein IIb/IIIa inhibitor use	148/1895 (7.8%)	98/1089 (9.0%)	0.08

*Estimated glomerular filtration rate <30 ml/min/1.73m² or dialysis at the time of screening. **Index procedure loading dose. PCI = percutaneous coronary intervention. CABG = coronary artery bypass graft surgery.

Table 3. Baseline angiographic features (core laboratory)

	BVS (N=2164) (L=2275)	CoCr-EES (N=1225) (L=1284)	P value
Number of lesions treated (any)*	1.1 ± 0.4	1.2 ± 0.4	0.63
Number of target lesions treated	1.1 ± 0.2	1.0 ± 0.2	0.67
- One target lesion	2045 (94.5%)	1162 (94.9%)	0.59
- Two target lesions	115 (5.3%)	61 (5.0%)	0.63
Target coronary artery (lesion level)			
- Left main	1 (0.0%)	0 (0.0%)	0.47
- Left anterior descending	1046 (46.0%)	575 (44.8%)	0.24
- Left circumflex	581 (25.5%)	357 (27.8%)	0.08
- Right	647 (28.4%)	352 (27.4%)	0.68
Lesion characteristics (lesion level)			
- Calcification (moderate or severe)	623/2267 (27.5%)	339/1277 (26.5%)	0.97
- Tortuosity (moderate or severe)	103/2268 (4.5%)	59/1277 (4.6%)	0.67
- Eccentric	1823/2267 (80.4%)	1014/1273 (79.7%)	0.81
- Bifurcation†	751/2268 (33.1%)	449/1274 (35.2%)	0.77
- Thrombus	8/2268 (0.4%)	4/1275 (0.3%)	0.99
- ACC/AHA class B2/C	1511/2270 (66.6%)	887/1276 (69.5%)	0.15
Quantitative measures (lesion level)			
- Reference vessel diameter, mm	2.68 ± 0.44	2.69 ± 0.46	0.79
- Minimal luminal diameter, mm	0.96 ± 0.37	0.95 ± 0.36	0.42
- Diameter stenosis, %	64.1 ± 12.4	64.6 ± 12.0	0.33
- Lesion length, mm	13.1 ± 5.6	13.4 ± 5.7	0.19

*Randomized target lesions plus non-randomized non-target lesions in a separate epicardial coronary artery.
†Defined by the angiographic core laboratory as having a side branch with diameter ≥1.5 mm. The protocol of each study excluded bifurcation lesions with a side branch diameter ≥2.0 mm by visual estimate. N = number of patients; L = number of target lesions.

Table 4. Procedural and angiographic results (core laboratory)

	BVS (N=2164) (L=2275)	CoCr-EES (N=1225) (L=1284)	P value
Number of study devices per patient	1.1 ± 0.4	1.1 ± 0.4	0.59
Total device length per lesion, mm	18.8 ± 6.9	19.6 ± 7.1	0.005
Overlapping study devices per lesion	159 (7.0%)	95 (7.4%)	0.30
Maximum device diameter per lesion, mm*	3.17 ± 0.41	3.16 ± 0.43	0.26
Maximum device pressure per lesion, atm*	15.5 ± 3.2	15.7 ± 3.3	0.52
Post-dilatation performed (per lesion)	1505 (66.2%)	710 (55.3%)	<0.0001
Bail-out device used (per lesion)	101 (4.4%)	72 (5.6%)	0.06
IVUS or OCT guidance (per procedure)	512/2141 (23.9%)	246/1210 (20.3%)	0.31
Post-PCI quantitative measures (lesion level)			
- Reference vessel diameter, mm	2.71 ± 0.44	2.75 ± 0.45	0.10
- In-device			
- Acute gain, mm	1.41 ± 0.45	1.58 ± 0.43	<0.0001
- Minimal luminal diameter, mm	2.37 ± 0.39	2.53 ± 0.40	<0.0001
- Diameter stenosis, %	12.4 ± 8.3	7.5 ± 8.2	<0.0001
- In-segment			
- Acute gain, mm	1.20 ± 0.45	1.24 ± 0.45	0.12
- Minimal luminal diameter, mm	2.16 ± 0.40	2.19 ± 0.43	0.31
- Diameter stenosis, %	19.9 ± 7.7	19.9 ± 8.4	0.78
Procedure duration, minutes	43.7 ± 23.7	39.7 ± 21.5	<0.0001
Device success (per lesion)	2144/2243 (95.6%)	1265/1272 (99.4%)	<0.0001
Procedure success (per patient)	2038/2148 (94.9%)	1176/1212 (97.0%)	0.007

N = number of patients; L = number of target lesions. *Device delivery system or post-dilatation balloon.
IVUS = intravascular ultrasound. OCT = optical coherence tomography.

Table 5. Independent predictors of ischemic events by logistic regression in the four ABSORB trials

	Relative risk [95%CI]	P value
3-year cumulative		
Target lesion failure		
Pre-procedure RVD (<2.25 mm vs. ≥2.25 mm)*	1.44 [1.14, 1.81]	0.003
Diabetes present	1.41 [1.15, 1.73]	0.001
Prior coronary interventions	1.41 [1.15, 1.73]	0.001
BVS (vs. CoCr-EES)	1.37 [1.09, 1.72]	0.005
Number of target lesions (2 vs. 1)	1.33 [1.03, 1.71]	0.04
Current tobacco use	1.25 [1.00, 1.57]	0.04
ABSORB China vs ABSORB III	0.50 [0.33, 0.76]	0.04
Device thrombosis		
BVS (vs. CoCr-EES)	3.95 [1.80, 8.67]	0.0006
Diabetes present	2.71 [1.62, 4.54]	0.0002
Pre-procedure RVD (<2.25 mm vs. ≥2.25 mm)*	1.90 [1.09, 3.32]	0.03
Between 1 and 3 years		
Target lesion failure		
Pre-procedure RVD (<2.25 mm vs. ≥2.25 mm)*	1.66 [1.16, 2.36]	0.005
Diabetes present	1.55 [1.16, 2.09]	0.003
BVS (vs. CoCr-EES)	1.50 [1.07, 2.09]	0.01
Current tobacco use	1.43 [1.04, 1.97]	0.03
Prior coronary intervention	1.34 [0.99, 1.80]	0.06
Pre-procedure MLD (< 0.93 mm vs. ≥ 0.93 mm)	0.74 [0.54, 1.01]	0.06
Female sex	0.65 [0.45, 0.94]	0.02

*Angiographic core laboratory determination. Device randomization was forced into each model. The following variables were entered into the models for target lesion failure: ACC/AHA lesion class, age (< median (63 years) vs ≥ median), treatment arm (BVS vs. CoCr-EES), calcification (moderate/severe), prior coronary interventions, any diabetes, hypercholesterolemia requiring treatment, sex, hypertension requiring treatment, presentation (ACS vs stable ischemia), bifurcation, target vessel (LAD vs non-LAD), target lesion length (median 12.16 mm), pre-procedure MLD (median 0.93 mm), number of treated lesions, P2Y12 receptor antagonist (loading), pre-procedure RVD (<2.25 mm vs ≥2.25 mm), current tobacco use.

Table 6. Subgroup analysis for the 3-year rate of target lesion failure among patients randomized in the 4 ABSORB trials

Subgroup		% (n/N)	Absorb BVS (N=2164)	XIENCE (N=1225)	Relative Risk [95% CI]*	P value Interaction*
Pre-procedural variables						
Age	< median (63 yrs)	47.6% (1610/3384)	11.1% (107/968)	7.9% (45/571)	1.29 [0.93, 1.80]	0.63
	≥ median	52.4% (1774/3384)	12.4% (136/1101)	8.4% (50/596)	1.45 [1.06, 1.97]	
Sex	Female	27.5% (932/3384)	11.1% (63/570)	8.8% (28/318)	1.18 [0.77, 1.80]	0.44
	Male	72.5% (2452/3384)	12.0% (180/1499)	7.9% (67/849)	1.46 [1.12, 1.91]	
Current smoking	Yes	23.1% (781/3384)	14.3% (66/463)	7.6% (21/278)	1.81 [1.13, 2.89]	0.24
	No	76.9% (2603/3384)	11.0% (177/1606)	8.3% (74/889)	1.26 [0.97, 1.63]	
Hypertension	Yes	74.6% (2524/3384)	12.1% (187/1546)	9.6% (82/856)	1.20 [0.94, 1.53]	0.04
	No	25.4% (860/3384)	10.7% (56/523)	4.2% (13/311)	2.56 [1.42, 4.62]	
Hyperlipidemia	Yes	70.6% (2390/3384)	12.4% (183/1470)	8.5% (69/811)	1.42 [1.10, 1.85]	0.57
	No	29.4% (994/3384)	10.0% (60/599)	7.3% (26/356)	1.24 [0.80, 1.94]	
Diabetes	Yes	30.2% (1020/3382)	13.9% (87/626)	12.6% (44/348)	1.06 [0.75, 1.48]	0.08
	No	69.8% (2362/3382)	10.6% (155/1462)	6.1% (51/835)	1.66 [1.22, 2.25]	
Prior MI	Yes	21.6% (727/3361)	13.7% (59/430)	12.1% (30/247)	1.05 [0.70, 1.58]	0.20
	No	78.4% (2634/3361)	11.2% (181/1623)	7.1% (65/915)	1.49 [1.14, 1.96]	
Prior intervention	Yes	33.7% (1141/3382)	14.5% (103/712)	12.4% (45/362)	1.14 [0.82, 1.58]	0.17
	No	66.3% (2241/3382)	10.3% (140/1357)	6.1% (49/803)	1.61 [1.17, 2.20]	
Presentation	ACS	32.5% (1100/3383)	11.2% (71/632)	7.7% (31/405)	1.27 [0.85, 1.91]	0.69
	Stable CAD	67.5% (2283/3383)	12.0% (172/1436)	8.4% (64/762)	1.42 [1.08, 1.87]	
No of target lesions	1	94.8% (3207/3383)	11.6% (226/1956)	8.2% (91/1108)	1.35 [1.07, 1.70]	0.44
	2	5.2% (176/3383)	15.0% (17/113)	6.8% (4/59)	1.97 [0.69, 5.61]	
P2Y12 loading	Clopidogrel/ticlopidine	77.0% (2560/3323)	11.2% (173/1549)	7.9% (72/906)	1.33 [1.02, 1.73]	0.41
	Prasugrel/ticagrelor	23.0% (763/3323)	13.6% (67/492)	8.1% (19/234)	1.66 [1.02, 2.70]	
RVD	< median (2.65 mm)	50.9% (1716/3372)	12.9% (139/1077)	11.3% (65/573)	1.12 [0.85, 1.47]	0.03
	≥ median	49.1% (1656/3372)	10.5% (104/988)	5.1% (30/589)	1.96 [1.32, 2.90]	

MLD	< median (0.93 mm)	51.4% (1734/3372)	11.8% (126/1065)	9.7% (58/599)	1.19 [0.88, 1.59]	0.13
	≥ median	48.6% (1638/3372)	11.7% (117/999)	6.6% (37/564)	1.68 [1.18, 2.40]	
Target lesion (mm)	< median (12.16 mm)	48.7% (1643/3371)	11.9% (119/1001)	7.2% (41/569)	1.56 [1.11, 2.19]	0.32
	≥ median	51.3% (1728/3371)	11.7% (124/1063)	8.9% (53/593)	1.25 [0.92, 1.70]	
ACC/AHA lesion	B2 or C	68.7% (2320/3376)	11.8% (165/1397)	9.4% (77/823)	1.21 [0.94, 1.57]	0.06
	A or B1	31.3% (1056/3376)	11.6% (78/671)	5.3% (18/340)	2.06 [1.25, 3.38]	
Target vessel	LAD	47.9% (1619/3383)	10.8% (108/1003)	9.6% (53/552)	1.06 [0.77, 1.44]	0.02
	Other	52.1% (1764/3383)	12.7% (135/1066)	6.8% (42/615)	1.79 [1.28, 2.49]	
Calcification	Moderate/Severe	28.0% (943/3369)	12.6% (73/581)	11.6% (37/319)	1.07 [0.74, 1.55]	0.10
	No//Mild	72.0% (2426/3369)	11.4% (169/1482)	6.9% (58/843)	1.55 [1.17, 2.07]	
Bifurcation	Yes	35.0% (1178/3368)	12.1% (86/711)	8.5% (36/424)	1.35 [0.93, 1.96]	0.89
	No	65.0% (2190/3368)	11.6% (157/1353)	8.0% (59/736)	1.38 [1.04, 1.84]	
Procedural variables						
Pre-dilatation	Yes	99.7% (3374/3383)	11.8% (243/2067)	8.2% (95/1161)	1.37 [1.09, 1.72]	-
	No	0.3% (9/3383)	0.0% (0/2)	0.0% (0/6)	-	
Max device diameter	< median (3.3 mm)	60.2% (2036/3382)	12.8% (160/1254)	9.0% (63/697)	1.36 [1.03, 1.79]	0.98
	≥ median	39.8% (1346/3382)	10.2% (83/815)	6.8% (32/469)	1.42 [0.96, 2.10]	
Post-dilatation	Yes	63.5% (2147/3380)	11.6% (161/1384)	7.2% (48/665)	1.50 [1.11, 2.05]	0.38
	No	36.5% (1233/3380)	12.0% (82/685)	9.4% (47/500)	1.23 [0.87, 1.73]	
Max balloon pressure	< median (16 atm)	43.4% (1469/3382)	11.3% (103/911)	9.3% (45/482)	1.18 [0.85, 1.65]	0.23
	≥ median	56.6% (1913/3382)	12.1% (140/1158)	7.3% (50/684)	1.55 [1.14, 2.11]	
IVUS/OCT	Yes	22.6% (756/3346)	12.1% (59/487)	6.8% (16/234)	1.78 [1.05, 3.03]	0.24
	No	77.4% (2590/3346)	11.3% (177/1562)	8.5% (78/918)	1.25 [0.97, 1.61]	
Device overlap	Yes	7.7% (260/3384)	14.1% (22/156)	12.1% (11/91)	1.18 [0.60, 2.34]	0.68
	No	92.3% (3124/3384)	11.6% (221/1913)	7.8% (84/1076)	1.40 [1.10, 1.78]	
Post-procedural variables						
RVD	< median (2.69 mm)	50.4% (1699/3369)	12.8% (138/1077)	10.9% (61/561)	1.16 [0.87, 1.54]	0.10
	≥ median	49.6% (1670/3369)	10.6% (104/985)	5.7% (34/601)	1.76 [1.21, 2.56]	

In-segment MLD	< median (2.15 mm)	50.9% (1715/3369)	13.0% (139/1066)	11.4% (67/586)	1.10 [0.84, 1.45]	0.02
	≥ median	49.1% (1654/3369)	10.3% (103/996)	4.9% (28/577)	2.03 [1.36, 3.05]	
In-device MLD	< median (2.41 mm)	50.5% (1700/3367)	13.0% (152/1167)	11.5% (54/468)	1.08 [0.80, 1.44]	0.10
	≥ median	49.5% (1667/3367)	10.1% (90/894)	5.9% (41/694)	1.65 [1.15, 2.35]	

* Adjusted for study in the logistic regression.

Table 7. Subgroup analysis for the 3-year rate of definite/probable stent thrombosis among patients randomized in the 4 ABSORB trials

Subgroup		% (n/N)	Absorb BVS (N=2164)	XIENCE (N=1225)	Relative Risk [95% CI]*	P value Interaction *
Pre-procedural variables						
Age	< median (63 yrs)	47.6% (1610/3384)	2.1% (20/960)	0.7% (4/565)	2.58 [0.88, 7.51]	0.39
	≥ median	52.4% (1774/3384)	2.8% (30/1089)	0.5% (3/589)	5.28 [1.62, 17.24]	
Sex	Female	27.5% (932/3384)	1.6% (9/565)	1.3% (4/313)	1.16 [0.36, 3.74]	0.03
	Male	72.5% (2452/3384)	2.8% (41/1484)	0.4% (3/841)	7.21 [2.24, 23.25]	
Current smoking	Yes	23.1% (781/3384)	3.3% (15/457)	0.0% (0/273)	-	-
	No	76.9% (2603/3384)	2.2% (35/1592)	0.8% (7/881)	2.59 [1.16, 5.82]	
Hypertension	Yes	74.6% (2524/3384)	2.4% (36/1526)	0.7% (6/844)	3.12 [1.32, 7.38]	0.44
	No	25.4% (860/3384)	2.7% (14/523)	0.3% (1/310)	7.49 [0.99, 56.81]	
Hyperlipidemia	Yes	70.6% (2390/3384)	2.9% (42/1454)	0.7% (6/804)	3.70 [1.58, 8.67]	0.96
	No	29.4% (994/3384)	1.3% (8/595)	0.3% (1/350)	4.56 [0.56, 36.94]	
Diabetes	Yes	30.2% (1020/3382)	4.4% (27/619)	1.2% (4/342)	3.52 [1.24, 9.97]	0.89
	No	69.8% (2362/3382)	1.6% (23/1428)	0.4% (3/812)	4.02 [1.21, 13.38]	
Prior MI	Yes	21.6% (727/3361)	1.9% (8/422)	0.8% (2/244)	2.20 [0.47, 10.33]	0.49
	No	78.4% (2634/3361)	2.5% (41/1611)	0.6% (5/905)	4.17 [1.65, 10.52]	
Prior intervention	Yes	33.7% (1141/3382)	3.0% (21/700)	0.6% (2/356)	5.21 [1.23, 22.09]	0.54
	No	66.3% (2241/3382)	2.1% (29/1349)	0.6% (5/796)	3.08 [1.20, 7.94]	
Presentation	ACS	32.5% (1100/3383)	1.9% (12/623)	0.2% (1/401)	6.70 [0.87, 51.73]	0.52
	Stable CAD	67.5% (2283/3383)	2.7% (38/1425)	0.8% (6/753)	3.22 [1.37, 7.59]	
No of target lesions	1	94.8% (3207/3383)	2.5% (48/1938)	0.6% (7/1096)	3.62 [1.64, 7.99]	-
	2	5.2% (176/3383)	1.8% (2/111)	0.0% (0/58)	-	
P2Y12 loading	Clopidogrel/ticlopidine	77.0% (2560/3323)	2.5% (38/1531)	0.6% (5/895)	4.06 [1.60, 10.28]	0.62
	Prasugrel/ticagrelor	23.0% (763/3323)	2.2% (11/490)	0.9% (2/232)	2.59 [0.58, 11.58]	
RVD	< median (2.65 mm)	50.9% (1716/3372)	2.4% (26/1066)	1.1% (6/564)	2.18 [0.90, 5.27]	0.10
	≥ median	49.1% (1656/3372)	2.5% (24/979)	0.2% (1/585)	13.43 [1.82, 99.02]	

MLD	< median (0.93 mm)	51.4% (1734/3372)	2.0% (21/1059)	1.0% (6/589)	1.82 [0.74, 4.48]	0.055
	≥ median	48.6% (1638/3372)	2.9% (29/985)	0.2% (1/561)	15.27 [2.08, 111.84]	
Target lesion (mm)	< median (12.16 mm)	48.7% (1643/3371)	2.1% (21/991)	0.7% (4/566)	2.81 [0.97, 8.13]	0.52
	≥ median	51.3% (1728/3371)	2.8% (29/1053)	0.5% (3/584)	4.89 [1.49, 16.02]	
ACC/AHA lesion	B2 or C	68.7% (2320/3376)	2.7% (37/1384)	0.7% (6/810)	3.37 [1.43, 7.96]	0.59
	A or B1	31.3% (1056/3376)	2.0% (13/664)	0.3% (1/340)	5.97 [0.79, 45.39]	
Target vessel	LAD	47.9% (1619/3383)	2.3% (23/996)	0.7% (4/546)	2.82 [0.98, 8.10]	0.51
	Other	52.1% (1764/3383)	2.6% (27/1053)	0.5% (3/608)	5.14 [1.56, 16.89]	
Calcification	Moderate/Severe	28.0% (943/3369)	2.4% (14/575)	1.0% (3/312)	2.38 [0.69, 8.19]	0.45
	No//Mild	72.0% (2426/3369)	2.4% (35/1468)	0.5% (4/837)	4.59 [1.64, 12.89]	
Bifurcation	Yes	35.0% (1178/3368)	2.7% (19/706)	0.7% (3/417)	3.41 [1.02, 11.46]	0.87
	No	65.0% (2190/3368)	2.3% (31/1338)	0.5% (4/730)	3.98 [1.41, 11.25]	
Procedural variables						
Pre-dilatation	Yes	99.7% (3374/3383)	2.4% (50/2047)	0.6% (7/1148)	3.73 [1.70, 8.20]	-
	No	0.3% (9/3383)	0.0% (0/2)	0.0% (0/6)	-	
Max device diameter	< median (3.3 mm)	60.2% (2036/3382)	2.8% (35/1241)	0.6% (4/690)	4.60 [1.64, 12.91]	0.53
	≥ median	39.8% (1346/3382)	1.9% (15/808)	0.6% (3/463)	2.64 [0.77, 9.05]	
Post-dilatation	Yes	63.5% (2147/3380)	2.1% (29/1370)	0.8% (5/657)	2.52 [0.98, 6.48]	0.25
	No	36.5% (1233/3380)	3.1% (21/679)	0.4% (2/495)	7.31 [1.72, 31.12]	
Max balloon pressure	< median (16 atm)	43.4% (1469/3382)	3.1% (28/905)	1.0% (5/477)	2.81 [1.09, 7.24]	0.38
	≥ median	56.6% (1913/3382)	1.9% (22/1144)	0.3% (2/676)	5.86 [1.38, 24.81]	
IVUS/OCT	Yes	22.6% (756/3346)	2.9% (14/483)	0.0% (0/234)	-	-
	No	77.4% (2590/3346)	2.3% (35/1547)	0.8% (7/906)	2.67 [1.19, 6.00]	
Device overlap	Yes	7.7% (260/3384)	2.6% (4/155)	1.1% (1/87)	2.19 [0.25, 19.55]	0.60
	No	92.3% (3124/3384)	2.4% (46/1894)	0.6% (6/1067)	4.01 [1.72, 9.37]	
Post-procedural variables						
RVD	< median (2.69 mm)	50.4% (1699/3369)	2.5% (27/1067)	1.1% (6/551)	2.24 [0.93, 5.39]	0.11
	≥ median	49.6% (1670/3369)	2.4% (23/975)	0.2% (1/598)	13.51 [1.83, 99.79]	

In-segment MLD	< median (2.15 mm)	50.9% (1715/3369)	2.4% (25/1057)	1.0% (6/576)	2.14 [0.88, 5.19]	0.09
	≥ median	49.1% (1654/3369)	2.5% (25/985)	0.2% (1/574)	13.86 [1.88, 102.02]	
In-device MLD	< median (2.41 mm)	50.5% (1700/3367)	2.6% (30/1155)	1.3% (6/458)	1.84 [0.77, 4.39]	0.06
	≥ median	49.5% (1667/3367)	2.3% (20/886)	0.1% (1/691)	14.61 [1.96, 108.74]	

* Adjusted for study in the logistic regression.

References

1. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, Van Boven AJ, Dominici M, Dudek D, McClean D, Helqvist S, Haude M, Reith S, de Sousa Almeida M, Campo G, Iniguez A, Sabate M, Windecker S and Onuma Y. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet*. 2016;388:2479-2491.

2. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H and Stone GW. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. *Eur Heart J*. 2015;36:3332-42.

3. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ and Stone GW. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. *J Am Coll Cardiol*. 2015;66:2298-309.

4. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C and Stone GW. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. *N Engl J Med*. 2015;373:1905-15.